Last reviewed · How we verify
Inavolisib (Dose #1) (inavolisib-dose-1)
At a glance
| Generic name | inavolisib-dose-1 |
|---|---|
| Sponsor | Pfizer Inc. |
| Phase | Phase 1 |
Approved indications
Common side effects
- Hyperglycaemia
- Fatigue
- Nausea
- Abdominal pain
- Diarrhoea
- Dysgeusia
- Dry mouth
- Stomatitis
- Constipation
- Weight decreased
- Vomiting
- Decreased appetite
Key clinical trials
- A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Inavolisib (Dose #1) CI brief — competitive landscape report
- Inavolisib (Dose #1) updates RSS · CI watch RSS
- Pfizer Inc. portfolio CI